BBI-001

DRUG2 trials

Sponsors

Bond Biosciences

Conditions

Hereditary Hemochromatosis

Phase 1

A Study to Evaluate BBI-001 in Hereditary Haemochromatosis (HH) Patients and Iron Deficient Volunteers

TerminatedNCT05238207

Bond BiosciencesHereditary Hemochromatosis

Start: 2022-03-28End: 2023-05-04Updated: 2023-08-02

A Study to Evaluate BBI-001 in Healthy Volunteers and in Patients With Hereditary Hemochromatosis

RecruitingNCT07371793

Bond BiosciencesHereditary Hemochromatosis

Start: 2026-05-04End: 2027-02-01Target: 34Updated: 2026-05-13

Related Papers

A phase 1b randomised clinical trial evaluating BBI-001, a non-absorbed oral therapeutic for the treatment of iron overload.

2025-05-17